Trodelvy’s Phase III Breast Cancer Results Raise More Questions Than Answers

While Gilead Sciences, Inc.’s Phase III TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) technically met its primary endpoint in third-line HR-positive/HER2-negative metastatic breast cancer (HR+/HER2- mBC), public statements by the company and a lack of details about progression-free survival (PFS) and overall survival (OS) data raised uncertainty about whether they would be enough to drive commercial adoption.

Gilead announced the study results on 7 March, but did not disclose any data, saying instead that the trial met its primary endpoint of showing a statistically significant improvement in PFS versus physician’s choice of chemotherapy, while noting that it had targeted a 30% improvement